Rocuronium requirements on the Paediatric Intensive Care Unit: the value of monitoring neuromuscular function

Submission date	Recruitment status	Prospectively registered
30/09/2004	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	Individual participant data
13/09/2013	Nervous System Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Oliver Bagshaw

Contact details

Birmingham Children's Hospital Department of Anaesthesia Steelhouse Lane Birmingham United Kingdom B4 6NH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0045125254

Study information

Scientific Title

Study objectives

Does monitoring neuromuscular function on PICU (Paediatric Intensive Care Unit) have any advantages over standard practice of clinical assessment of neuromuscular function/drug requirements?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Nervous System Diseases: Neuromuscular function

Interventions

Patients randomly allocated to received either standard management of NMBD (neuromuscular blocking drug) administration or protocol driven according to monitored neuromuscular function.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

- 1. Total amount of NMBD administered
- 2. Speed of recovery or neuromuscular function once NMBDs stopped
- 3. Complications related to residual NM paralysis

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/06/2002

Completion date

31/05/2003

Eligibility

Key inclusion criteria

30 patients under the age of 16 years requiring administration of Rocuronium to facilitate mechanical ventilation for more than 48 hours.

Participant type(s)

Patient

Age group

Child

Upper age limit

16 Years

Sex

Not Specified

Target number of participants

30

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/06/2002

Date of final enrolment

31/05/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Birmingham Children's Hospital Birmingham United Kingdom B4 6NH

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Government

Funder Name

Birmingham Children's Hospital NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration